aldosterone synthase inhibitor

FW In Conversation: Mineralys CEO Jon Congleton on Reviving Hypertension Innovation and Lorundrostat’s Best-in-Class Potential

1 week ago talkbio0Tagged aldosterone synthase inhibitor, conversation, For which was done, Hypertensive disease, Jon Congleton, Lorundrostat, Mineralys

Mineralys Therapeutics; Jon Congleton; lorundrostat; aldosterone synthase inhibitor; hypertension treatment; FW In Conversation

AstraZeneca Makes Strong Case for Baxdrostat with Detailed 24-Hour Data in Resistant Hypertension Trial

3 months ago talkbio0Tagged 24-Hour Data, aldosterone synthase inhibitor, AstraZeneca, baxdrostat, Blood Pressure, blood pressure ambulatory, Phase 3 Clinical Trials, Resistant hypertensive disorder, safety profile

AstraZeneca; baxdrostat; resistant hypertension; phase III trial; aldosterone synthase inhibitor; blood pressure; 24-hour data; ambulatory blood pressure; safety profile

AstraZeneca gears up for FDA filing after baxdrostat’s phase 3 hypertension success

5 months ago talkbio0Tagged aldosterone synthase inhibitor, AstraZeneca, baxdrostat, File (record), Hypertensive disease, regulatory approval, United States Food and Drug Administration

AstraZeneca; baxdrostat; hypertension; FDA filing; aldosterone synthase inhibitor; phase 3 trial; regulatory approval